Lyell Immunopharma (LYEL) Liabilities and Shareholders Equity (2020 - 2026)

Lyell Immunopharma's Liabilities and Shareholders Equity history runs 7 years deep, the most recent figure standing at $350.6 million for Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity fell 18.42% year-over-year to $350.6 million; the TTM figure through Mar 2026 stood at $1.5 billion (down 32.36% YoY), while the FY2025 annual figure was $340.1 million, down 30.72% from the prior year.
• Liabilities and Shareholders Equity came in at $350.6 million for Q1 2026 at Lyell Immunopharma, up from $340.1 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $1.1 billion in Q1 2022 to a low of $340.1 million in Q4 2025.
• A 5-year average of $684.8 million and a median of $694.2 million in 2024 frame the typical range for Liabilities and Shareholders Equity.
• Across the five-year window, Liabilities and Shareholders Equity fell 16.84% in 2022 and sank 41.08% in 2025, its largest moves.
• Lyell Immunopharma's Liabilities and Shareholders Equity stood at $937.6 million in 2022, then dropped by 20.0% to $750.0 million in 2023, then plunged by 34.55% to $490.9 million in 2024, then sank by 30.72% to $340.1 million in 2025, then increased by 3.11% to $350.6 million in 2026.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $350.6 million, $340.1 million, and $408.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison